<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03233308</url>
  </required_header>
  <id_info>
    <org_study_id>AR-13324-CS206</org_study_id>
    <nct_id>NCT03233308</nct_id>
  </id_info>
  <brief_title>Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)</brief_title>
  <official_title>A Double-Masked, Randomized, Placebo-Controlled Study of Trabecular Outflow Facility Following Treatment With Netarsudil Ophthalmic Solution 0.02% (AR-13324) in Subjects With Elevated Intraocular Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aerie Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aerie Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the effect on trabecular outflow facility of Netarsudil ophthalmic solution 0.02%
      compared to placebo
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from baseline in the mean diurnal trabecular outflow facility</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the mean intraocular pressure</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in the mean episcleral venous pressure</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All treatment-emergent AEs that occurs or worsens on or after the first treatment</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed and change from baseline in visual acuity</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of anterior segment by slit-lamp biomicroscopy from baseline</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Primary Open Angle Glaucoma or Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Netarsudil Ophthalmic Solution 0.02%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Netarsudil ophthalmic solution 0.02%; 1 drop daily, in the morning (QD AM), topical ocular; one eye for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Netarsudil ophthalmic solution placebo; 1 drop in the morning (QD AM) on contralateral eye for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Netarsudil Ophthalmic Solution</intervention_name>
    <description>Topical sterile ophthalmic solution once daily</description>
    <arm_group_label>Netarsudil Ophthalmic Solution 0.02%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>Topical sterile ophthalmic solution once daily</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Must be 18 years of age or older

          2. Diagnosis of open angle glaucoma or ocular hypertension in both eyes

          3. Unmedicated intraocular pressure &gt;20 mmHg and &lt; 30 mmHg in both eyes at first
             qualification visit

          4. Corrected visual acuity equivalent to 20/200

          5. Able to give informed consent and follow study instructions

        Exclusion Criteria:

        Ophthalmic

          1. Clinically significant ocular disease

          2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure
             glaucoma, or narrow angles

          3. Intraocular pressure ≥30 mmHg in either eye

          4. A difference in IOP between eyes &gt;4mmHg at qualification visit

          5. Use of more than two ocular hypotensive medications within 30 days of screening

          6. Known hypersensitivity to any component of the formulation

          7. Previous glaucoma surgery or refractive surgery

          8. Report of ocular injury in either eye within the six months prior to screening or
             ocular or non-refractive surgery within 3 months prior to screening

          9. Recent or current ocular infection or inflammation in either eye

         10. Use of ocular medication in either eye of any kind within 30 days of screening

         11. Mean central corneal thickness greater than 620 μm in either eye

         12. Any abnormality preventing reliable applanation tonometry of either eye

             Systemic:

         13. Clinically significant abnormalities in any recent laboratory tests within 6 weeks
             prior to screening

         14. Clinically significant systemic disease

         15. Participation in any investigational study within 60 days prior to screening

         16. Use of systemic medication that could have an effect on intraocular pressure within 30
             days prior to screening

         17. Women who are pregnant, nursing, planning a pregnancy, or not using a medically
             acceptable form of birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Ramirez-Davis</last_name>
    <role>Study Director</role>
    <affiliation>Aerie Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nancy Ramirez-Davis</last_name>
    <phone>888-594-5111</phone>
    <email>nramirez@aeriepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jae Lopez</last_name>
    <phone>888-594-5111</phone>
    <email>jlopez@aeriepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>July 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2017</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

